David Schlett joins Prime Therapeutics as Chief Financial Officer
Schlett is an experienced finance executive with more than 25 years of business, leadership experience. More about David's role at Prime
News from Prime
Prime applies a price-to-value framework for high cost drugs. This helps drive a productive dialogue based on the value a drug can deliver to a a patient’s life.
Collaboration leverages scale and capabilities to drive greater value.
Just 0.03 percent of members have annual drug costs over $250,000. They account for 9 percent of total drug spend.
Prime in the news
The New York Times
Twin Cities Business
Minneapolis/St. Paul Business Journal